Market Research Logo

The US Specialty Pharmaceutical Market: Industry Analysis & Outlook (2017-2021)



The US pharmaceutical market is segregated into two types of drugs majorly i.e. traditional drugs and specialty drugs. Specialty drugs in recent times have gained a strong foothold in the US and are likely to experience robust growth in the coming years, with majority of the pharmaceutical companies heading their research and development initiatives towards these drugs.

Specialty drugs are basically meant for chronic and rare disease. Drugs in this category are very expensive and difficult to administer. Also, these drugs require proper management and special handling making them costly. Since, a large part of population in the US is ageing into diseases like cancer, and other deadly diseases, the demand for specialty drugs has skyrocketed in recent times.

The US specialty pharmaceutical market has changed over the span of five years with a lot of these drugs being in their final phase of development. The US specialty pharmaceutical market is likely to grow at staggering growth rate in the coming years majorly due to factors like ageing population of the US, improving life expectancy, rise in real net per capita medicine spending on specialty drugs, and high prevalence of chronic disease in the region.

The market is also undergoing some notable changes that have been covered in the report. The market growth is likely to be hindered by abandonment rate of specialty medicines and high R&D costs. The report offers an in-depth analysis of the “The US Specialty Pharmaceutical Market: Industry Analysis & Outlook (2017-2021)”. Major pharmaceutical companies that have been covered in the report include Celgene Corporation, Gilead Sciences Inc., Amgen Inc., and AbbVie Inc.


1. Market Overview
1.1 Introduction
Table 1: Specialty Pharmaceuticals - Key Application Areas
1.2 Specialty Pharmaceuticals Vs Traditional Drugs
1.3 Application of Specialty Pharmaceuticals
1.4 Specialty Pharmacy Services
1.5 Specialty Product Distribution
Table 2: Flow of Products within the Specialty Pharmacy Channel
Table 3: Specialty Pharmacy v/s Specialty Distributors
1.6 Specialty Pharma Manufacturer Services
1.7 Value Proposition of Specialty Pharmacy
Table 4: SP Benefits Model
2. The US Pharmaceutical Market Analysis
2.1 The US Pharmaceutical Market by Value
Table 5: The US Pharmaceutical Market by Value (2012-2016)
2.2 The US Pharmaceutical Market Forecast by Value
Table 6: The US Pharmaceutical Market Forecast by Value (2017-2021)
2.3 The US Pharmaceutical Market by Segment
2.3.1 The US Pharmaceutical Market by Segment
Table 7: The US Pharmaceutical Market by Segment (2016)
2.3.2 The US Pharmaceutical Market by Segment Forecast
Table 8: The US Pharmaceutical Market by Segment Forecast (2021)
2.3.3 The US Traditional Pharmaceutical Market by Value
Table 9: The US Traditional Pharmaceutical Market by Value (2012-2016)
2.3.4 The US Traditional Pharmaceutical Market Forecast by Value
Table 10: The US Traditional Pharmaceutical Market Forecast by Value (2017-2021)
2.4 The US Pharmaceutical Market’s Demand Growth
Table 11: The US Pharmaceutical Market’s Demand Growth by Segment (2012-2016)
2.5 The US Pharmaceutical Market’s Drug Approval by Segment
Table 12: The US Pharmaceutical Market’s Drug Approval by Segment (2016)
2.6 The US Pharmaceutical Market by Drugs
Table 13: The US Pharmaceutical Market by Top 10 Drugs (2016)
3. The US Specialty Pharmaceutical Market
3.1 The US Specialty Pharmaceutical Market by Value
Table 14: The US Specialty Pharmaceutical Market by Value (2012-2016)
3.2 The US Specialty Pharmaceutical Market Forecast by Value
Table 15: The US Specialty Pharmaceutical Market Forecast by Value (2017-2021)
3.3 The US Specialty Pharmaceutical Market by Drugs
Table 16: The US Specialty Pharmaceutical Market by Parameters (2016)
3.4 The US Specialty Pharmaceutical- Prescription Volume
3.4.1 The US Specialty Medication Prescription Volume
Table 17: The US Specialty Medication Prescription Volume (2012-2016)
3.4.2 The US Specialty Medication Prescription Volume Forecast
Table 18: The US Specialty Medication Prescription Volume Forecast (2017-2021)
3.4.3 The US Specialty Medication Prescription Volume by Therapeutic Class
Table 19: The US Specialty Medication Prescription Volume by Therapeutic Class (2016)
3.4.4 The US Specialty Medication Prescription Volume Forecast by Therapeutic Class
Table 20: The US Specialty Medication Prescription Volume Forecast by Therapeutic Class (2021)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rise in Ageing Population of the US
Table 21: The US Ageing Population by Age Bracket (2012-2016)
4.1.2 Improving Life Expectancy
Table 22: The US Life Expectancy-65 Years and Above (2012-2016)
4.1.3 Surge in Spending on Medicines
Table 23: Total Spending on Medicines in the US (2012-2016)
Table 24: Real Net Per Capita Medicine Spending on Specialty Drugs (2012-2016)
4.1.4 Escalating Per Capita Heath Expenditure in the US
Table 25: Total Per Capita Health Expenditure in the US (2012-2017)
4.1.5 Prevalence of Chronic Disease in the US
Table 26: Prevalence of Chronic Disease in the US (2015-2030)
4.2 Trend and Opportunities
4.2.1 Technology Enabled Transformation
4.2.2 Growing Foothold of Oncology Segment
4.2.3 Specialty Pharmacy Mergers and Acquisitions
Table 27: Specialty Pharmacy Mergers and Acquisitions in the US (2016)
4.3 Challenges and Issues
4.3.1 High Cost of Drugs
Table 28: Price Range of Most Expensive Specialty Drugs in the US (2016)
4.3.2 Abandonment Rates for Branded Medicines
Table 29: Abandonment Rates for Branded Medicines in Commercial Plans (2016)
4.3.3 High R&D Costs
5. Competitive Landscape
5.1 The US Specialty Pharmaceutical Market
5.1.1 Revenue Comparison by Major Players
Table 30: The US Specialty Pharmaceutical Market Revenue Comparison by Major Players (2016)
5.2 The US Specialty Pharmaceutical Market by Therapeutic Class
5.2.1 The US Specialty Inflammatory Conditions Market Share by Drugs
Table 31: The US Specialty Inflammatory Conditions Market Share by Drugs (2016)
5.2.2 The US Specialty Oncology Market Share by Drugs
Table 32: The US Specialty Oncology Market Share by Drugs (2016)
5.2.3 The US Specialty Multiple Sclerosis Market Share by Drugs
Table 33: The US Specialty Multiple Sclerosis Market Share by Drugs (2016)
5.2.4 The US Specialty HIV Market Share by Drugs
Table 34: The US Specialty HIV Market Share by Drugs (2016)
5.2.5 The US Specialty Hepatitis C Market Share by Drugs
Table 35: The US Specialty Hepatitis C Market Share by Drugs (2016)
5.3 The US Specialty Drug Pharmacies Market Share
Table 36: The US Specialty Drug Pharmacies Market Share (2016)
5.4 The US Specialty Product Distribution Market Share
Table 37: The US Specialty Product Distribution Market Share by Company (2016)
6. Company Profiles
6.1 Gilead Sciences Inc.
6.1.1 Business Overview
Table 38: Gilead Sciences Inc. Revenue Share by Product (2016)
6.1.2 Financial Overview
Table 39: Gilead Sciences Inc. Revenue and Net Income (2012-2016)
6.1.3 Business Strategies
6.2 AbbVie Inc.
6.2.1 Business Overview
Table 40: AbbVie Inc. Revenue Share by Products (2016)
6.2.2 Financial Overview
Table 41: AbbVie Inc. Revenue and Net Earnings (2012-2016)
6.2.3 Business Strategies
6.3 Amgen Inc.
6.3.1 Business Overview
Table 42: Amgen Inc. Revenue Share by Region (2016)
6.3.2 Financial Overview
Table 43: Amgen Inc. Revenue and Net Income (2012-2016)
6.3.3 Business Strategies
Table 44: Amgen Inc. Product Developments (2016)
6.4 Celgene Corporation
6.4.1 Business Overview
Table 45: Celgene Corporation’s Revenue Share by Products (2016)
6.4.2 Financial Overview
Table 46: Celgene Corporation’s Revenue and Net Income (2012-2016)
6.4.3 Business Strategies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report